 Jennifer Laudadio
Concepts (135)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papillomavirus Infections | 4 | 2015 | 163 | 1.260 |
Why?
| | Papillomaviridae | 3 | 2015 | 107 | 0.960 |
Why?
| | Keratosis, Seborrheic | 2 | 2015 | 5 | 0.630 |
Why?
| | Vulvar Diseases | 2 | 2015 | 7 | 0.620 |
Why?
| | Alphapapillomavirus | 2 | 2014 | 16 | 0.580 |
Why?
| | Pathology | 1 | 2015 | 43 | 0.510 |
Why?
| | Fusion Proteins, bcr-abl | 3 | 2009 | 23 | 0.490 |
Why?
| | Curriculum | 2 | 2022 | 429 | 0.460 |
Why?
| | Neoplasm Invasiveness | 2 | 2012 | 295 | 0.460 |
Why?
| | Genomics | 1 | 2015 | 310 | 0.450 |
Why?
| | Uterine Cervical Dysplasia | 1 | 2013 | 51 | 0.440 |
Why?
| | Perineum | 1 | 2012 | 24 | 0.420 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2009 | 48 | 0.420 |
Why?
| | Myxoma | 1 | 2012 | 14 | 0.420 |
Why?
| | Mutagenesis, Insertional | 2 | 2008 | 28 | 0.410 |
Why?
| | Vulvar Neoplasms | 1 | 2012 | 54 | 0.400 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2013 | 276 | 0.370 |
Why?
| | Mass Screening | 1 | 2013 | 370 | 0.360 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2007 | 278 | 0.320 |
Why?
| | Introns | 1 | 2008 | 49 | 0.320 |
Why?
| | Protein Kinase Inhibitors | 2 | 2013 | 216 | 0.300 |
Why?
| | Genes, erbB-2 | 1 | 2007 | 8 | 0.300 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2010 | 384 | 0.300 |
Why?
| | Head and Neck Neoplasms | 1 | 2010 | 335 | 0.290 |
Why?
| | Actinomyces | 1 | 2006 | 9 | 0.290 |
Why?
| | Actinomycosis | 1 | 2006 | 10 | 0.290 |
Why?
| | Vaginal Smears | 1 | 2006 | 31 | 0.290 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2005 | 54 | 0.260 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2005 | 173 | 0.240 |
Why?
| | DNA, Viral | 2 | 2014 | 142 | 0.210 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 117 | 0.200 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 531 | 0.190 |
Why?
| | Humans | 19 | 2022 | 54284 | 0.190 |
Why?
| | Female | 12 | 2015 | 28441 | 0.170 |
Why?
| | Middle Aged | 7 | 2014 | 13088 | 0.160 |
Why?
| | Breast Neoplasms | 1 | 2007 | 1248 | 0.150 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2015 | 46 | 0.130 |
Why?
| | Prognosis | 4 | 2015 | 2118 | 0.130 |
Why?
| | Mucositis | 1 | 2014 | 9 | 0.130 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2014 | 14 | 0.120 |
Why?
| | Histocytochemistry | 1 | 2014 | 46 | 0.120 |
Why?
| | Microscopy | 1 | 2014 | 66 | 0.120 |
Why?
| | Quinazolines | 1 | 2013 | 39 | 0.120 |
Why?
| | Human Papillomavirus DNA Tests | 1 | 2013 | 2 | 0.120 |
Why?
| | Protein Structure, Tertiary | 3 | 2009 | 289 | 0.120 |
Why?
| | Virology | 1 | 2013 | 9 | 0.120 |
Why?
| | Bile Duct Diseases | 1 | 2013 | 11 | 0.110 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2013 | 40 | 0.110 |
Why?
| | United States Food and Drug Administration | 1 | 2013 | 97 | 0.110 |
Why?
| | Genotype | 1 | 2014 | 599 | 0.110 |
Why?
| | Phosphotransferases | 2 | 2009 | 24 | 0.100 |
Why?
| | RNA, Messenger | 2 | 2013 | 1202 | 0.100 |
Why?
| | Clinical Competence | 1 | 2015 | 446 | 0.100 |
Why?
| | Aged | 5 | 2014 | 10054 | 0.100 |
Why?
| | Piperazines | 2 | 2009 | 116 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 164 | 0.100 |
Why?
| | Cholelithiasis | 1 | 2011 | 11 | 0.100 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2011 | 24 | 0.100 |
Why?
| | Pyrimidines | 2 | 2009 | 196 | 0.100 |
Why?
| | In Situ Hybridization | 1 | 2010 | 82 | 0.100 |
Why?
| | Endosonography | 1 | 2011 | 96 | 0.090 |
Why?
| | Smoking | 1 | 2014 | 556 | 0.090 |
Why?
| | Algorithms | 1 | 2013 | 697 | 0.090 |
Why?
| | HIV Infections | 1 | 2013 | 394 | 0.080 |
Why?
| | Exons | 1 | 2008 | 105 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1136 | 0.080 |
Why?
| | United States | 2 | 2022 | 5217 | 0.080 |
Why?
| | DNA Mutational Analysis | 1 | 2008 | 217 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2013 | 642 | 0.080 |
Why?
| | Adult | 6 | 2022 | 14207 | 0.070 |
Why?
| | Proto-Oncogenes | 1 | 2007 | 29 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2014 | 3431 | 0.070 |
Why?
| | Gene Amplification | 1 | 2007 | 57 | 0.070 |
Why?
| | Receptor, erbB-2 | 1 | 2007 | 79 | 0.070 |
Why?
| | Base Sequence | 1 | 2008 | 719 | 0.070 |
Why?
| | Amino Acid Sequence | 1 | 2008 | 767 | 0.070 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 980 | 0.070 |
Why?
| | Cell Division | 1 | 2007 | 330 | 0.070 |
Why?
| | Young Adult | 2 | 2013 | 4318 | 0.070 |
Why?
| | Male | 7 | 2014 | 27334 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1089 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 923 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2022 | 6432 | 0.060 |
Why?
| | Disease-Free Survival | 2 | 2014 | 485 | 0.060 |
Why?
| | Antineoplastic Agents | 4 | 2014 | 1300 | 0.050 |
Why?
| | Adolescent | 3 | 2011 | 6897 | 0.050 |
Why?
| | Mutation | 1 | 2009 | 1501 | 0.050 |
Why?
| | Pathology, Molecular | 1 | 2022 | 24 | 0.050 |
Why?
| | Accreditation | 1 | 2022 | 72 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2005 | 644 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2014 | 692 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 225 | 0.040 |
Why?
| | Benzamides | 2 | 2009 | 54 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2014 | 5604 | 0.040 |
Why?
| | Molecular Imaging | 1 | 2015 | 60 | 0.030 |
Why?
| | Cyclin D3 | 1 | 2013 | 6 | 0.030 |
Why?
| | Survival | 1 | 2013 | 16 | 0.030 |
Why?
| | Taxoids | 1 | 2013 | 45 | 0.030 |
Why?
| | Cyclin D1 | 1 | 2013 | 60 | 0.030 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2013 | 69 | 0.030 |
Why?
| | Radiotherapy | 1 | 2014 | 138 | 0.030 |
Why?
| | Anti-Retroviral Agents | 1 | 2013 | 18 | 0.030 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2013 | 12 | 0.030 |
Why?
| | Jaundice | 1 | 2013 | 19 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2013 | 106 | 0.030 |
Why?
| | Patient Compliance | 1 | 2014 | 249 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 401 | 0.030 |
Why?
| | Cholestasis | 1 | 2013 | 45 | 0.030 |
Why?
| | Syndrome | 1 | 2013 | 252 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2013 | 569 | 0.030 |
Why?
| | Technetium Tc 99m Lidofenin | 1 | 2011 | 1 | 0.030 |
Why?
| | Ursodeoxycholic Acid | 1 | 2011 | 5 | 0.030 |
Why?
| | Cholagogues and Choleretics | 1 | 2011 | 6 | 0.030 |
Why?
| | Cholangiography | 1 | 2011 | 10 | 0.030 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2011 | 8 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 36 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 180 | 0.020 |
Why?
| | Ceftriaxone | 1 | 2011 | 29 | 0.020 |
Why?
| | Cisplatin | 1 | 2013 | 352 | 0.020 |
Why?
| | Age of Onset | 1 | 2011 | 117 | 0.020 |
Why?
| | Antibiotic Prophylaxis | 1 | 2011 | 67 | 0.020 |
Why?
| | Radiography, Interventional | 1 | 2011 | 65 | 0.020 |
Why?
| | Pancreatitis | 1 | 2011 | 58 | 0.020 |
Why?
| | Biopsy | 1 | 2013 | 692 | 0.020 |
Why?
| | Neurosurgical Procedures | 1 | 2011 | 120 | 0.020 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2009 | 36 | 0.020 |
Why?
| | Comorbidity | 1 | 2011 | 663 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 508 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1056 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2008 | 418 | 0.020 |
Why?
| | Liver | 1 | 2013 | 1225 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2011 | 2387 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 1213 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2011 | 1033 | 0.010 |
Why?
| | Child | 1 | 2011 | 7341 | 0.010 |
Why?
|
|
Laudadio's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
|